PCV20 vaccine study for kids and young adults with rheumatic diseases
Treatments studied
Part of Immune system & allergy clinical trials.
This study tests if a pneumonia vaccine (PCV20) is safe and works well in children and young adults with certain autoimmune rheumatic diseases like juvenile arthritis, lupus, or dermatomyositis. It aims to help protect them from serious infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 2 and 25 years old
- You have been diagnosed with juvenile idiopathic arthritis, juvenile systemic lupus erythematosus, or juvenile dermatomyositis
- Your disease is stable right now
- You have not had a severe allergic reaction to any vaccine component
- You have not received a blood transfusion in the last 6 months
- You have not gotten any other vaccine in the past 4 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether stopping methotrexate for a short time before getting the pneumonia vaccine (PCV20) helps your body build a stronger immune response. It is for people with autoimmune rheumatic diseases like rheumatoid arthritis or lupus whose disease is under control.
This trial tests a catch-up pneumococcal vaccine for children and adolescents who may have missed some doses. It aims to see how safe and effective the vaccine is in healthy kids aged 15 months to 17 years.
This study tests a new vaccine that protects against 21 types of bacteria that cause pneumonia and other infections. It is for healthy infants around 2 months old to see if it works as well as the current vaccine.
This trial tests a newer pneumonia vaccine (PCV21) in older veterans with weakened immune systems who have already received an older pneumonia vaccine (PPSV23). It aims to see if the new vaccine provides better protection.
This trial tests a single dose of a new pneumococcal vaccine (21-valent) in children and teens with sickle cell disease. It aims to see if the vaccine can help protect against serious infections caused by pneumococcus bacteria, which are especially dangerous for people with SCD.
This study tests a new pneumococcal vaccine (PCV15) to see how well it protects against carrying the bacteria that can cause pneumonia. Healthy adults aged 18–50 who have not had a pneumococcal vaccine in the last 5 years may join.
Hear when a new Autoimmune Rheumatologic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.